No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Mizuho Securities Maintains In8bio(INAB.US) With Buy Rating, Maintains Target Price $2
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
JonesTrading Maintains In8bio(INAB.US) With Buy Rating, Maintains Target Price $1.2
IN8bio's Promising Leukemia Program and Strategic Partnerships Drive Buy Rating
IN8bio Is Maintained at Buy by HC Wainwright & Co.
IN8bio Analyst Ratings